17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.

ABSTRACT:

Background

17-alpha Hydroxyprogesterone caproate for prevention of recurrent preterm birth is recommended for use in the United States.

Objective

We sought to assess the clinical effectiveness of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth ≤35 weeks compared to similar births in our obstetric population prior to the implementation of 17-alpha hydroxyprogesterone caproate.

Study design

This was a prospective cohort study of 17-alpha hydroxyprogesterone caproate in our obstetric population. The primary outcome was the recurrence of birth ≤35 weeks for the entire study cohort compared to a historical referent rate of 16.8% of recurrent preterm birth in our population. There were 3 secondary outcomes. First, did 17-alpha hydroxyprogesterone ca

SUBMITTER: Nelson DB 

PROVIDER: S-EPMC5449222 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature